Answers are grounded in this paper and cite their sources.
Fibroblast activation protein (FAP), a type II transmembrane serine protease highly expressed in cancer-associated fibroblasts (CAFs), represents an attractive target for tumor imaging and targeted therapy. In this study, we designed and synthesized a series of FAP-targeted dimers (FAPI-FUSCC-DIMER) based on the UAMC1110 scaffold incorporating structurally diverse linkers and evaluated these compounds using a stepwise screening strategy to identify a promising FAP-targeted theranostic radioligand candidate. All FAPI-FUSCC-DIMER derivatives were efficiently labeled with 68Ga and exhibited favorable radiochemical stability and hydrophilic properties. Selected compounds were further evaluated in vivo based on SPR affinity assays and cell uptake studies. Micro-PET/CT imaging and biodistribution studies further evaluated the tumor uptake and retention profiles of the FAPI-FUSCC-DIMER series. FAPI-FUSCC-DIMER-2 demonstrated high FAP affinity, enhanced tumor uptake and prolonged tumor retention, with favorable pharmacokinetic properties, and was subsequently selected for 177Lu-based radioligand therapy studies. [177Lu]Lu-FAPI-FUSCC-DIMER-2 exhibited prolonged tumor retention for up to 120 h and a strong inhibitory effect on tumor growth in the HT-1080-FAP tumor model, together with a favorable safety profile. These findings support continued preclinical investigation of FAPI-FUSCC-DIMER-2.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: